Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1

Conditions

Multiple Myeloma 147Lymphoma, Follicular 40Lymphoma, Large B-Cell, Diffuse 37Lymphoma, B-Cell, Marginal Zone 24Recurrence 18Lymphoma, Mantle-Cell 17Lymphoma 17Neoplasms, Plasma Cell 15Lymphoma, Non-Hodgkin 15Leukemia, Lymphocytic, Chronic, B-Cell 11Neoplasms 9Smoldering Multiple Myeloma 8Lymphoma, B-Cell 8Neoplasm, Residual 5Burkitt Lymphoma 5Leukemia, Plasma Cell 4Waldenstrom Macroglobulinemia 3Myelodysplastic Syndromes 3Lymphoma, T-Cell, Peripheral 3Lymphoma, T-Cell, Cutaneous 3Plasmacytoma 2Pancreatic Neoplasms 2Neuroblastoma 2Lymphoma, T-Cell 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Leukemia 2Hodgkin Disease 2Hematologic Diseases 2Urinary Bladder Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 7X-Rays 6Specimen Handling 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 5Biopsy 5ulixertinib 2trametinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2larotrectinib 2ivosidenib 2erdafitinib 2ensartinib 2dabrafenib 2LY3023414 2olaparib 1etoposide phosphate 1cobimetinib 1Vemurafenib 1Sirolimus 1Pharmacogenomic Variants 1Lenalidomide 1Genetic Testing 1Etoposide 1Cyclophosphamide 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Histiocytosis, Langerhans-Cell × Lenalidomide × 1 year × Clear all
NCT02523040 2025-12-10

Lenalidomide for Adult Histiocyte Disorders

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
12 enrolled 14 charts
MyeloidSarcoma

Histiocytosis, Langerhans-Cell, Erdheim-Chester Disease, Histiocytic Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡